Claims Intelligence and Referral Leakage
Editorial revision: . Original publication and source dates are retained.
Use claims analysis to decide which service lines and provider relationships warrant investment, then test whether targeted action can recover the identified opportunity.
Return to insightsOperators, analytics leaders, and founders who need claims data to influence field motion. / Evergreen framework
The strategic question
Which referral, specialty, or payer corridor is leaking enough value to justify a focused commercial motion?
I treat claims intelligence as a capital-allocation instrument. A pattern of out-of-network utilization can justify investigation; it does not establish recoverable demand. The patient may prefer another clinician, require a service the network cannot provide, lack usable coverage or already receive appropriate care elsewhere. The investment question is which portion of the observed flow can be addressed through a clinically appropriate service the organization can actually deliver.
That distinction changes the denominator. Start with observed utilization, exclude services outside the organization’s clinical and contractual scope, then test geography, appointment availability, referral relationships and patient choice. Only the remaining opportunity belongs in the commercial plan. A large data universe is useful for discovery, but the field team needs a much smaller set of accounts where a specific action could change an actual care pathway.
I would compare an additional dollar of referral development with an additional dollar of intake or clinical capacity. If qualified patients cannot obtain appointments, more outreach enlarges the queue. If usable appointments remain empty because referring clinicians do not understand the service or the intake process is unreliable, commercial investment may be appropriate. The claims analysis should help identify that constraint rather than assume demand generation is always the answer.
Operating model
Allocate to recoverable demand and usable capacity.
Build the economic case from incremental completed care. The planning identity is addressable patients × incremental completion attributable to the intervention × collectible contribution per completed episode, less outreach, intake and added capacity costs. This is an analytical structure, not a forecast. Use the organization’s own contracts and cost behavior, and show how the result changes when attribution, collection or conversion falls below plan.
Collection and contribution matter more than billed charges. A new referral can consume scarce appointments, displace another patient or require additional staff before it produces cash. Capacity already funded and capacity that must be purchased have different economics. I would therefore rank opportunities by expected incremental contribution and access improvement per constrained resource, while keeping clinical appropriateness and patient choice as independent requirements.
Test a defined referral corridor against a credible comparison before expanding the field effort. Track the path from identified account to accepted referral, scheduled visit, completed service and collected payment. Include rejected referrals and cancellations. If the intervention increases referrals but leaves completion unchanged, investigate intake and receiving capacity before increasing acquisition spend. The decision is whether this corridor merits further resources, not whether the dashboard can display a larger market.
Operating framework
- 01
Define the clinically and contractually addressable population by service line, payer and referral corridor.
- 02
Remove utilization the network cannot appropriately serve; retain uncertainty around patient choice and incomplete records.
- 03
Rank corridors by expected incremental contribution per constrained appointment or staff hour.
- 04
Stage field investment against accepted referrals, incremental completed care and collectible contribution.
Metrics that matter
- 01
Addressable patients after clinical, coverage and capacity exclusions
- 02
Available appointments and intake hours by target corridor
- 03
Incremental collectible contribution after outreach and delivery cost
- 04
Incremental completed episodes versus the comparison cohort
Red flags
Projected demand exceeds receiving capacity, and the plan omits the cost of expanding it.
Observed utilization is priced as recoverable revenue without testing coverage, patient choice or clinical fit.
Referral growth is credited as incremental value without accounting for displaced patients or uncollected payment.
CEO and CFO questions
Which corridor produces the highest incremental contribution within our staffed capacity, and who might be displaced?
Does the binding constraint require field investment, intake capacity, a payer agreement or a different clinical service?
What incremental completion and collection thresholds justify expansion after acquisition and delivery costs?
Discuss the strategic decision